Biocon registers consolidated revenue of Rs 4519 crore in Q3
Advertisement
Bengaluru: Bengaluru, Biocon Ltd, the Bengaluru-based pharmaceutical giant has announced its consolidated financial results for the fiscal third quarter ended December 31, 2023.
Kiran Mazumdar Shaw, Executive Chairperson, Biocon and Biocon Biologics said that Biocon delivered consolidated Revenue of Rs 4,519 crore for Q3FY24, driven by 65 per cent growth in Biosimilars and 9 per cent growth in Research Services. Consolidated EBITDA at Rs 1,492 crore grew by 106 per cent. Net Profit, boosted by other income, stood at Rs 660 crore.
"A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of $200 million towards the acquisition-related debt reduction. Steady market shares for key biosimilar in the US and EU were complemented by the Emerging Markets performance which saw a number of new product launches and tender wins.
"We continue to make steady progress towards strengthening the foundation for sustainable growth across all three business segments," Shaw stated.
"The Generics business delivered 4 per cent sequential revenue growth in the third quarter, driven by higher API sales. The year-on-year performance, however, was muted on account of continued pricing pressure that impacted customer offtake in our API business, compared to the previous fiscal. This was partially offset by growth in our Generic Formulations portfolio. While we expect pricing pressure in the API business to persist, we continue our focus on driving cost and execution efficiencies throughout the business, to mitigate future impact," said Siddharth Mittal, CEO and Managing Director, Biocon Limited.
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company.
BBL has acquired the global biosimilars business of its long-standing partner Viatris. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., EU, Australia, Canada, Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other noncommunicable diseases.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.